Surgical interventions for women with stress urinary incontinence: systematic review and network meta-analysis of randomised controlled trials

Mari Imamura, Jemma Hudson, Sheila A Wallace, Graeme MacLennan, Michal Shimonovich, Muhammad Imran Omar, Mehdi Javanbakht, Eoin Moloney, Frauke Becker, Laura Ternent, Isobel Montgomery, Phil Mackie, Lucky Saraswat, Ash Monga, Luke Vale, Dawn Craig, Miriam Brazzelli, Mari Imamura, Jemma Hudson, Sheila A Wallace, Graeme MacLennan, Michal Shimonovich, Muhammad Imran Omar, Mehdi Javanbakht, Eoin Moloney, Frauke Becker, Laura Ternent, Isobel Montgomery, Phil Mackie, Lucky Saraswat, Ash Monga, Luke Vale, Dawn Craig, Miriam Brazzelli

Abstract

Objectives: To compare the effectiveness and safety of surgical interventions for women with stress urinary incontinence.

Design: Systematic review and network meta-analysis.

Eligibility criteria for selecting studies: Randomised controlled trials evaluating surgical interventions for the treatment of stress urinary incontinence in women.

Methods: Identification of relevant randomised controlled trials from Cochrane reviews and the Cochrane Incontinence Specialised Register (searched May 2017), which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Medline In-Process, Medline Epub Ahead of Print, CINAHL, ClinicalTrials.gov, and WHO ICTRP. The reference lists of relevant articles were also searched. Primary outcomes were "cure" and "improvement" at 12 months, analysed by means of network meta-analyses, with results presented as the surface under the cumulative ranking curve (SUCRA). Adverse events were analysed using pairwise meta-analyses. Risk of bias was assessed using the Cochrane risk of bias tool. The quality of evidence for network meta-analysis was assessed using the GRADE approach.

Results: 175 randomised controlled trials assessing a total of 21 598 women were included. Most studies had high or unclear risk across all risk of bias domains. Network meta-analyses were based on data from 105 trials that reported cure and 120 trials that reported improvement of incontinence symptoms. Results showed that the interventions with highest cure rates were traditional sling, retropubic midurethral sling (MUS), open colposuspension, and transobturator MUS, with rankings of 89.4%, 89.1%, 76.7%, and 64.1%, respectively. Compared with retropubic MUS, the odds ratio of cure for traditional sling was 1.06 (95% credible interval 0.62 to 1.85), for open colposuspension was 0.85 (0.54 to 1.33), and for transobtrurator MUS was 0.74 (0.59 to 0.92). Women were also more likely to experience an improvement in their incontinence symptoms after receiving retropubic MUS or transobturator MUS compared with other surgical procedures. In particular, compared with retropubic MUS, the odds ratio of improvement for transobturator MUS was 0.76 (95% credible interval 0.59 to 0.98), for traditional sling was 0.69 (0.39 to 1.26), and for open colposuspension was 0.65 (0.41 to 1.02). Quality of evidence was moderate for retropubic MUS versus transobturator MUS and low or very low for retropubic MUS versus the other two interventions. Data on adverse events were available mainly for mesh procedures, indicating a higher rate of repeat surgery and groin pain but a lower rate of suprapubic pain, vascular complications, bladder or urethral perforation, and voiding difficulties after transobturator MUS compared with retropubic MUS. Data on adverse events for non-MUS procedures were sparse and showed wide confidence intervals. Long term data were limited.

Conclusions: Retropubic MUS, transobturator MUS, traditional sling, and open colposuspension are more effective than other procedures for stress urinary incontinence in the short to medium term. Data on long term effectiveness and adverse events are, however, limited, especially around the comparative adverse events profiles of MUS and non-MUS procedures. A better understanding of complications after surgery for stress urinary incontinence is imperative.

Systematic review registration: PROSPERO CRD42016049339.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; LV reports grants from the NIHR systematic reviews funding stream outside the submitted work and is a member of funding panel NIHR HTA CET panel until march 2018 and coordinating editor of the Cochrane Incontinence Group; AM was a paid speaker for Astellas, SEP Pharma, Boston Scientific, and Atlantic; no other relationships or activities that could appear to have influenced the submitted work.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Fig 1
Fig 1
PRISMA flowchart of study selection
Fig 2
Fig 2
Network plot for number of women showing cure (top panel) and improvement (bottom panel) of stress urinary incontinence symptoms. Circle size reflects number of women and line width reflects number of direct comparisons
Fig 3
Fig 3
Surface under cumulative ranking curves (SUCRA) for number of women showing cure of urinary incontinence symptoms
Fig 4
Fig 4
Surface under cumulative ranking curves (SUCRA) for number of women showing improvement of urinary incontinence symptoms
Fig 5
Fig 5
Repeat surgery for stress urinary incontinence, adverse events, and resource use (only events reported by >5 studies). *Effect estimate is standardised mean difference. MUS=midurethral sling
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6549286/bin/imam048205.va.jpg

References

    1. Milsom I, Altman D, Cartwright R, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI). In: Abrams P, Cardozo L, Wagg A, Wein A, eds. Incontinence: 6th International Consultation on Incontinence, Tokyo, September 2016. 6th ed. International Continence Society (ICS) and International Consultation on Urological Diseases (ICUD) 2017:1-141.
    1. MacArthur C, Glazener CM, Wilson PD, Lancashire RJ, Herbison GP, Grant AM. Persistent urinary incontinence and delivery mode history: a six-year longitudinal study. BJOG 2006;113:218-24. 10.1111/j.1471-0528.2005.00818.x
    1. MacLennan AH, Taylor AW, Wilson DH, Wilson D. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. BJOG 2000;107:1460-70. 10.1111/j.1471-0528.2000.tb11669.x
    1. Thom DH, van den Eeden SK, Brown JS. Evaluation of parturition and other reproductive variables as risk factors for urinary incontinence in later life. Obstet Gynecol 1997;90:983-9. 10.1016/S0029-7844(97)00537-1
    1. Fultz NH, Burgio K, Diokno AC, Kinchen KS, Obenchain R, Bump RC. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003;189:1275-82.
    1. Tincello D, Sculpher M, Tunn R, et al. Patient characteristics impacting health state index scores, measured by the EQ-5D of females with stress urinary incontinence symptoms. Value Health 2010;13:112-8.
    1. Papanicolaou S, Pons ME, Hampel C, et al. Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study. Maturitas 2005;52(Suppl 2):S35-47. 10.1016/j.maturitas.2005.09.004
    1. Turner DA, Shaw C, McGrother CW, Dallosso HM, Cooper NJ, MRC Incontinence Team The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 2004;93:1246-52. 10.1111/j.1464-410x.2004.04806.x
    1. Subak LL, Brubaker L, Chai TC, et al. Urinary Incontinence Treatment Network High costs of urinary incontinence among women electing surgery to treat stress incontinence. Obstet Gynecol 2008;111:899-907. 10.1097/AOG.0b013e31816a1e12
    1. Kinchen KS, Burgio K, Diokno AC, Fultz NH, Bump R, Obenchain R. Factors associated with women’s decisions to seek treatment for urinary incontinence. J Womens Health (Larchmt) 2003;12:687-98. 10.1089/154099903322404339
    1. Shaw C, Tansey R, Jackson C, Hyde C, Allan R. Barriers to help seeking in people with urinary symptoms. Fam Pract 2001;18:48-52. 10.1093/fampra/18.1.48
    1. Shaw C, Das Gupta R, Williams KS, Assassa RP, McGrother C. A survey of help-seeking and treatment provision in women with stress urinary incontinence. BJU Int 2006;97:752-7. 10.1111/j.1464-410X.2006.06071.x
    1. Hunskaar S. A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women. Neurourol Urodyn 2008;27:749-57. 10.1002/nau.20635
    1. Sievert K-D, Abufaraj M, Kernig K, et al. Sling surgery for female incontinence. Eur Urol Suppl 2018;17:109-18. 10.1016/j.eursup.2017.12.003.
    1. Gibson W, Wagg A. Are older women more likely to receive surgical treatment for stress urinary incontinence since the introduction of the mid-urethral sling? An examination of Hospital Episode Statistics data. BJOG 2016;123:1386-92. 10.1111/1471-0528.13338.
    1. Keltie K, Elneil S, Monga A, et al. Complications following vaginal mesh procedures for stress urinary incontinence: an 8 year study of 92,246 women. Sci Rep 2017;7:12015. 10.1038/s41598-017-11821-w.
    1. Oliphant SS, Wang L, Bunker CH, Lowder JL. Trends in stress urinary incontinence inpatient procedures in the United States, 1979-2004. Am J Obstet Gynecol 2009;200:521.
    1. Jonsson Funk M, Levin PJ, Wu JM. Trends in the surgical management of stress urinary incontinence. Obstet Gynecol 2012;119:845-51. 10.1097/AOG.0b013e31824b2e3e.
    1. Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997;89:501-6. 10.1016/S0029-7844(97)00058-6.
    1. Fialkow MF, Newton KM, Lentz GM, Weiss NS. Lifetime risk of surgical management for pelvic organ prolapse or urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:437-40. 10.1007/s00192-007-0459-9.
    1. Wu JM, Matthews CA, Conover MM, Pate V, Jonsson Funk M. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol 2014;123:1201-6. 10.1097/AOG.0000000000000286.
    1. Wilkins MF, Wu JM. Lifetime risk of surgery for stress urinary incontinence or pelvic organ prolapse. Minerva Ginecol 2017;69:171-7. 10.23736/S0026-4784.16.04011-9.
    1. Morling JR, McAllister DA, Agur W, et al. Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study. Lancet 2017;389:629-40. 10.1016/S0140-6736(16)32572-7.
    1. Drugwatch. Transvaginal mesh verdicts and settlements. Orlando (FL): ; 2018.
    1. Souders CP, Eilber KS, McClelland L, et al. The truth behind transvaginal mesh litigation: devices, timelines, and provider characteristics. Female Pelvic Med Reconstr Surg 2018;24:21-5. 10.1097/SPV.0000000000000433.
    1. Scottish Government. The Scottish Independent Review of the use, safety and efficacy of transvaginal mesh implants in the treatment of stress urinary incontinence and pelvic organ prolapse in women: final report. Edinburgh: The Scottish Government 2017 .scot/Resource/0051/00515856.pdf
    1. Department of Health and Social Care. Update on the Independent Medicines and Medical Devices Safety Review, 10 July 2018: written statement - HCWS841. London: UK Parliament; 2018.
    1. Department of Health. Minister for Health Simon Harris announces pause in the use of transvaginal mesh devices - press release: 24 July 2018. Dublin, Ireland: Department of Health, Government of Ireland; 2018.
    1. Rehman H, Bezerra CCB, Bruschini H, Cody JD. Traditional suburethral sling operations for urinary incontinence in women. Cochrane Database Syst Rev 2011;(1):CD001754. 10.1002/14651858.CD001754.pub3.
    1. Nambiar A, Cody JD, Jeffery ST. Single-incision sling operations for urinary incontinence in women. Cochrane Database Syst Rev 2014;(6):CD008709. 10.1002/14651858.CD008709.pub2.
    1. Lapitan MCM, Cody JD. Open retropubic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev 2016;2:CD002912. 10.1002/14651858.CD002912.pub6.
    1. Kirchin V, Page T, Keegan PE, Atiemo K, Cody JD, McClinton S. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2012;(2):CD003881. 10.1002/14651858.CD003881.pub3.
    1. Glazener CMA, Cooper K. Bladder neck needle suspension for urinary incontinence in women. Cochrane Database Syst Rev 2014;(12):CD003636. 10.1002/14651858.CD003636.pub3.
    1. Glazener CMA, Cooper K. Anterior vaginal repair for urinary incontinence in women. Cochrane Database Syst Rev 2001;(1):CD001755. 10.1002/14651858.CD001755.
    1. Ford AA, Rogerson L, Cody JD, Ogah J. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev 2015;(7):CD006375.
    1. Dean NM, Ellis G, Wilson PD, Herbison GP. Laparoscopic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev 2006;(3):CD002239. 10.1002/14651858.CD002239.pub2.
    1. Brazzelli M, Javanbakht M, Imamura M, et al. The Effectiveness and cost-effectiveness of Surgical Treatments for womEn with stRess urinary incontinence: An evidence synthesis, economic evaluation and discrete choice experiment (ESTER). Health Technol Assess 2019;23:1-306.
    1. Incontinence C. Specialised Register. Cochrane Incontinence, 2018, .
    1. Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane Bias Methods Group. Cochrane Statistical Methods Group The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. 10.1136/bmj.d5928.
    1. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37. 10.1023/A:1008929526011.
    1. StataCorp. Stata Statistical Software: Release 14 [computer program]. College Station, TX: StataCorp LP 2015.
    1. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. Originally published 2011; last updated April 2014. Sheffield, UK: NICE Decision Support Unit, 2014. (accessed 22 August 2017)
    1. Henriksson L, Ulmsten U. A urodynamic evaluation of the effects of abdominal urethrocystopexy and vaginal sling urethroplasty in women with stress incontinence. Am J Obstet Gynecol 1978;131:77-82. 10.1016/0002-9378(78)90478-7
    1. Mirosh M, Epp A. TVT vs laparoscopic Burch colposuspension for the treatment of stress urinary incontinence (Abstract number 640). Proceedings of the International Continence Society (ICS), 35th Annual Meeting; 2005 Aug 28-Sep 2, Montreal, Canada. 2005.
    1. Stangel-Wojcikiewicz K. Laparoscopic burch colposuspension compared to laparotomy for treatment urinary stress incontinence. [Abstract No 121]. Neurourol Urodyn 2008;27:714.
    1. David-Montefiore E, Frobert JL, Grisard-Anaf M, et al. Peri-operative complications and pain after the suburethral sling procedure for urinary stress incontinence: a French prospective randomised multicentre study comparing the retropubic and transobturator routes. Eur Urol 2006;49:133-8. 10.1016/j.eururo.2005.09.019
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. 10.1136/bmj.327.7414.557.
    1. Puhan MA, Schünemann HJ, Murad MH, et al. GRADE Working Group A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 10.1136/bmj.g5630.
    1. US Food and Drug Administration. Considerations about surgical mesh for SUI (last updated 7 January 2018). Silver Spring (MD): US Food and Drug Administration; 2018.
    1. European Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). Final opinion on the safety of surgical meshes used in urogynecological surgery. Luxembourg: DG Health and Food Safety, Public Health, European Commission; 2015.
    1. Administraton TG. (TGA). TGA actions after review into urogynaecological surgical mesh implants - first published 22 December 2017; updated 17 January 2018. Department of Health, Australian Government, 2018, .
    1. Medsafe. Safety information: surgical mesh implants - regulatory action on surgical mesh products: 31 January 2018. Wellington, New Zealand: New Zealand Medicines and Medical Devices Safety Authority, Ministry of Health, New Zealand Government; 2018.
    1. NHS England. Mesh Oversight Group Report. Leeds, UK: NHS England; 2017.
    1. Ogah J, Cody JD, Rogerson L. Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev 2009;(4):CD006375. 10.1002/14651858.CD006375.pub2.
    1. Rimmer A. Vaginal mesh procedures need compulsory register, says royal college. BMJ 2018;360:k586. 10.1136/bmj.k586.
    1. Heneghan CJ, Goldacre B, Onakpoya I, et al. Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process. BMJ Open 2017;7:e017125. 10.1136/bmjopen-2017-017125.
    1. Heneghan C, Godlee F. Surgical mesh and patient safety. BMJ 2018;363:k4231. 10.1136/bmj.k4231.

Source: PubMed

3
Suscribir